Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

IQVIA Report: Biopharma R&D Investment Increased 32 Percent Over Last 5 Years

The IQVIA report finds that in 2018, 27% of drugs launched were for cancer or its symptoms, and 20% were for infectious diseases.

Read More »

Teva stops testing migraine drug as cluster headache treatment

Teva Pharmaceutical Industries Ltd. will stop developing the migraine drug Ajovy for treating cluster headaches after finding the treatment was unlikely to meet the main goal of a late-stage trial.

Read More »

Amgen sets $21,900 annual price for new Evenity bone drug

Amgen Inc. set the U.S. list price for the company’s new Evenity osteoporosis drug at $1,825 a month, or $21,900 for a full 12-month course of injections.

Read More »

Janssen Presents Landmark Data From Invokana Study

Janssen’s Invokana became the only medicine in nearly 20 years and the first diabetes medicine ever to demonstrate a reduction in progression to end-stage renal failure in T2D patients with CKD.

Read More »

Alnylam’s RNAi Therapy for Acute Hepatic Porphyria Positive in Phase III

Cambridge, Mass.-based Alnylam Pharmaceuticals indicated that the company’s ENVISION Phase III trial of givosiran was positive for acute hepatic porphyria (AHP).

Read More »

FDA Approves Expanded Label for Keytruda

The U.S. FDA approved an expanded label for Merck’s anti-PD-1 therapy Keytruda as monotherapy for the first-line treatment of patients with stage III non-small cell lung cancer who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC, and whose tumors express PD-L1 as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.

Read More »

AskBio Snags $235 Million Investment to Drive Gene Therapy Development

Asklepios BioPharmaceutical (AskBio) secured a $235 million investment from Vida Ventures and TPG Capital.

Read More »

Janssen Presents New Data From First Phase 3 Trial Of Single-Tablet Regimen In Rapid Initiation Model Of Care Demonstrating Safety, Efficacy With Symtuza Through 48 Weeks

The Janssen Pharmaceutical Companies of Johnson & Johnson unveiled new 48-week data for Symtuza (darunavir 800 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg D/C/F/TAF) showing that a high proportion of HIV patients achieved an undetectable viral load through 48 weeks after rapidly starting Symtuza.

Read More »

Advocacy Group and FDA Advisor Call for a Moratorium on Opioid Approvals

As America continues to grapple with the opioid crisis, nonprofit advocacy group Public Citizen is calling for the U.S. Food and Drug Administration (FDA) to place a moratorium on the approval of any new opioid medications.

Read More »

AbbVie’s Humira Remains Top-Selling Rx Drug for 2018

AbbVie’s Humira, the world’s top-selling prescription medicine since 2012, brought the Illinois-based company nearly $20 billion in revenue in 2018.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!

Subscribe

Ad Right Bottom